Latest & greatest articles for gabapentin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on gabapentin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on gabapentin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for gabapentin

21. Narcotics, Benzodiazepines, Stimulants, and Gabapentin: Policies, Initiatives, and Practices Across Canada, 2014

Narcotics, Benzodiazepines, Stimulants, and Gabapentin: Policies, Initiatives, and Practices Across Canada, 2014 Narcotics, Benzodiazepines, Stimulants, and Gabapentin: Policies, Initiatives, and Practices Across Canada, 2014 | CADTH.ca Find the information you need Narcotics, Benzodiazepines, Stimulants, and Gabapentin: Policies, Initiatives, and Practices Across Canada, 2014 Narcotics, Benzodiazepines, Stimulants, and Gabapentin: Policies, Initiatives, and Practices Across Canada, 2014 (...) , as well as place a significant burden on our health, social services, and public safety systems.” 1 The purpose of this Environmental Scan is to provide an overview of policies, practices, and initiatives which the publicly funded drug programs, colleges of physicians and surgeons, and colleges of pharmacy are implementing across Canada to address the misuse, abuse, and diversion of prescription narcotics (opioids), benzodiazepines, stimulants, and gabapentin. This information may assist drug policy

2015 Canadian Agency for Drugs and Technologies in Health - Environmental Scanning

22. Epidural steroid injections compared with gabapentin for lumbosacral radicular pain: multicenter randomized double blind comparative efficacy study. (PubMed)

Epidural steroid injections compared with gabapentin for lumbosacral radicular pain: multicenter randomized double blind comparative efficacy study. To evaluate whether an epidural steroid injection or gabapentin is a better treatment for lumbosacral radiculopathy.A multicenter randomized study conducted between 2011 and 2014. Computer generated randomization was stratified by site. Patients and evaluating physicians were blinded to treatment outcomes.Eight military, Veterans Administration (...) global perceived effect. All patients had one month follow-up visits; patients whose condition improved remained blinded for their three month visit.There were no significant differences for the primary outcome measure at one month (mean pain score 3.3 (SD 2.6) and mean change from baseline -2.2 (SD 2.4) in epidural steroid injection group versus 3.7 (SD 2.6) and -1.7 (SD 2.6) in gabapentin group; adjusted difference 0.4, 95% confidence interval -0.3 to 1.2; P=0.25) and three months (mean pain score

Full Text available with Trip Pro

2015 BMJ Controlled trial quality: predicted high

23. Gabapentin for Adults with Neuropathic Pain

Gabapentin for Adults with Neuropathic Pain Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types (...) , posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Gabapentin for Adults with Neuropathic Pain: A Review of the Clinical Efficacy

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

24. Randomized controlled trial of gabapentin as an adjunct to perioperative analgesia in total hip arthroplasty patients (PubMed)

Randomized controlled trial of gabapentin as an adjunct to perioperative analgesia in total hip arthroplasty patients Gabapentin was investigated as a single-dose adjunct to morphine for postoperative pain management. The primary objective was to determine if gabapentin given preoperatively and for two days postoperatively as part of multimodal analgesia would decrease postoperative morphine consumption in patients undergoing primary total hip arthroplasty (THA).The study group included 102 (...) patients aged 19-90 years who were undergoing primary THA in a single joint with no contraindications to the study medications, no chronic pain syndrome, and no chronic opioid use. Intervention group patients (n = 48) received gabapentin 600 mg po preoperatively and 200 mg postoperatively on the day of surgery. They were continued on gabapentin at 200 mg three times daily for two days. Control group patients (n = 54) received placebo in a similar fashion. Preoperatively, all patients were given 30 mg

Full Text available with Trip Pro

2015 EvidenceUpdates Controlled trial quality: predicted high

25. Gabapentin and pregabalin: major adverse effects

Gabapentin and pregabalin: major adverse effects Prescrire IN ENGLISH - Spotlight ''Gabapentin and pregabalin: major adverse effects'', 1 November 2014 {1} {1} {1} | | > > > Gabapentin and pregabalin: major adverse effects Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Gabapentin and pregabalin: major adverse effects To reduce the consequences (...) of some severe adverse effects associated with gabapentin or pregabalin, it is advisable not to expose patients to them other than in situations where these drugs have proved to be highly effective. Gabapentin and pregabalin are used in certain epilepsies and for pain in neurological diseases. Pregabalin is also used to treat anxiety disorders. According to a review of French pharmacovigilance data published in 2013, between 1995 and 2009, 2415 adverse effects linked to gabapentin or pregabalin were

2014 Prescrire

26. Gabapentin Is as Effective as an Occlusal Appliance in Controlling Nighttime Masticatory EMG Activity

Gabapentin Is as Effective as an Occlusal Appliance in Controlling Nighttime Masticatory EMG Activity UTCAT2762, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Gabapentin Is as Effective as an Occlusal Appliance in Controlling Nighttime Masticatory EMG Activity Clinical Question In a patient with fixed orthodontic bands and nighttime parafunctional habits, is gabapentin as effective and safe as an oral appliance (...) in reducing levels of nighttime masticatory EMG activity? Clinical Bottom Line Gabapentin (200 or 300 mg at bedtime) is a good treatment option for reducing nighttime masticatory EMG activity when an occlusal appliance cannot be used; it also has a good safety profile. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Madani/2012 20 patients (stabilization splint group [n = 10] and gabapentin group [n = 10

2014 UTHSCSA Dental School CAT Library

27. Do venlafaxine and gabapentin control hot flashes in women with a history of breast cancer?

Do venlafaxine and gabapentin control hot flashes in women with a history of breast cancer? Do venlafaxine and gabapentin control hot flashes in women with a history of breast cancer? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Do venlafaxine and gabapentin control hot flashes in women with a history of breast (...) cancer? View/ Open Date 2012-12 Format Metadata Abstract Venlafaxine reduces hot flashes more than placebo in women with a history of breast cancer; adverse effects include dry mouth and constipation (strength of recommendation [SOR]: B, randomized clinical trials [RCTs] with heterogeneous outcomes). Gabapentin also reduces hot flashes more than placebo (SOR: B, a single RCT); adverse effects include dizziness and somnolence (SOR: C, standard reference). After having tried both medications, women

2014 Clinical Inquiries

28. Gabapentin

Gabapentin USE OF GABAPENTIN IN PREGNANCY 0344 892 0909 USE OF GABAPENTIN IN PREGNANCY (Date of issue: November 2014 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Gabapentin is an antiepileptic drug indicated as monotherapy (...) or adjunctive therapy in the treatment of partial seizures with or without secondary generalisation, and for the treatment of peripheral neuropathic pain. The available data concerning gabapentin exposure in pregnancy consist of relatively small prospective cohort studies (n=8) and ten case reports/series. Most data relates to gabapentin use in pregnancy for the treatment of maternal epilepsy. A few case reports/series describe use of gabapentin in the treatment of neuropathic pain or hyperemesis gravidarum

2014 UK Teratology Information Service

29. Gabapentin for adults with neuropathic pain: a review of the clinical evidence and guidelines

Gabapentin for adults with neuropathic pain: a review of the clinical evidence and guidelines Gabapentin for adults with neuropathic pain: a review of the clinical evidence and guidelines Gabapentin for adults with neuropathic pain: a review of the clinical evidence and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) CADTH. Gabapentin for adults with neuropathic pain: a review of the clinical evidence and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions Indirect evidence suggests similar short-term pain relief with gabapentin compared with pregabalin, tricyclic antidepressants and serotonin norepinephrine reuptake inhibitors in patients with painful diabetic neuropathy, postherpetic neuralgia and fibromyalgia. There is lower quality

2014 Health Technology Assessment (HTA) Database.

30. Narcotics, benzodiazepines, stimulants, and gabapentin: policies, initiatives, and practices across Canada, 2014

Narcotics, benzodiazepines, stimulants, and gabapentin: policies, initiatives, and practices across Canada, 2014 Narcotics, benzodiazepines, stimulants, and gabapentin: policies, initiatives, and practices across Canada, 2014 Narcotics, benzodiazepines, stimulants, and gabapentin: policies, initiatives, and practices across Canada, 2014 CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation CADTH. Narcotics, benzodiazepines, stimulants, and gabapentin: policies, initiatives, and practices across Canada, 2014. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Environmental Scans; issue 45. 2014 Authors' conclusions The survey of Canada's publicly funded drug plans, colleges of physicians and surgeons, and colleges of pharmacists shows that jurisdictions have established multiple avenues to address the issue

2014 Health Technology Assessment (HTA) Database.

31. Gabapentin and pregabalin in the management of postoperative pain after lumbar spinal surgery: a systematic review and meta-analysis (PubMed)

Gabapentin and pregabalin in the management of postoperative pain after lumbar spinal surgery: a systematic review and meta-analysis Systematic review and meta-analysis.To review the literature systematically and make a comprehensive understanding of the efficacy of these 2 drugs in the management of postoperative pain after lumbar spinal surgery.Several trials that evaluated the efficacy of gabapentin and pregabalin in the management of postoperative pain after lumbar spinal surgery have been (...) published.PubMed (1980 to present), adapted for EMBASE (1980 to present), and Cochrane databases were searched for randomized placebo-controlled trials. Random effect model was used in our meta-analysis, and standard mean difference (SMD) was chosen as the pooled estimate.Seven trials were included in our study. All included studies could be considered to be of high quality in methodology. The pooled results from meta-analysis demonstrated that compared with placebo, both gabapentin and pregabalin could

2013 EvidenceUpdates

32. Gabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial (PubMed)

Gabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial Approved medications for alcohol dependence are prescribed for less than 9% of US alcoholics.To determine if gabapentin, a widely prescribed generic calcium channel/γ-aminobutyric acid-modulating medication, increases rates of sustained abstinence and no heavy drinking and decreases alcohol-related insomnia, dysphoria, and craving, in a dose-dependent manner.A 12-week, double-blind, placebo-controlled, randomized dose (...) -ranging trial of 150 men and women older than 18 years with current alcohol dependence, conducted from 2004 through 2010 at a single-site, outpatient clinical research facility adjoining a general medical hospital.Oral gabapentin (dosages of 0 [placebo], 900 mg, or 1800 mg/d) and concomitant manual-guided counseling.Rates of complete abstinence and no heavy drinking (coprimary) and changes in mood, sleep, and craving (secondary) over the 12-week study. RESULTS Gabapentin significantly improved

Full Text available with Trip Pro

2013 EvidenceUpdates Controlled trial quality: predicted high

33. Intrathecal gabapentin to treat chronic intractable noncancer pain (PubMed)

Intrathecal gabapentin to treat chronic intractable noncancer pain Oral gabapentin is approved as an anticonvulsant medication and to treat postherpetic neuralgia. Its nonopioid properties and presumed spinal site of analgesic action made the study on intrathecal gabapentin attractive to establish the minimum effective dose for a later, pivotal trial.The authors examined the safety and efficacy of intrathecal gabapentin in a randomized, blinded, placebo-controlled, multicenter trial (...) in a heterogeneous cohort of candidates with chronic pain for intrathecal drug therapy.Patients (N = 170) were randomized to receive continuous intrathecal gabapentin (0 [placebo], 1, 6, or 30 mg/day) during 22 days of blinded treatment after implantation of a permanent drug delivery system. The highest dose, 30 mg/day, was selected to maintain a safety margin below the 100-mg/day dose that was explored in a phase 1 study. The authors found no statistically significant difference in the primary outcome measure

Full Text available with Trip Pro

2013 EvidenceUpdates Controlled trial quality: uncertain

34. Gabapentin add-on for drug-resistant partial epilepsy. (PubMed)

Gabapentin add-on for drug-resistant partial epilepsy. The majority of people with epilepsy have a good prognosis and their seizures are well controlled by a single antiepileptic drug, but up to 30% develop drug-resistant epilepsy, especially those with partial seizures. In this review we summarise the current evidence regarding the antiepileptic drug gabapentin, when used as an add-on treatment for drug-resistant partial epilepsy.To evaluate the efficacy and tolerability of gabapentin when (...) of gabapentin in people with drug-resistant partial epilepsy. Trials using an active drug control group or which compared doses of gabapentin were also included in the review.Two review authors independently selected trials for inclusion and extracted the relevant data. We assessed the following outcomes: (a) seizure frequency and seizure freedom; (b) treatment withdrawal (any reason); (c) adverse effects. Primary analyses were intention-to-treat. We also undertook sensitivity best and worst-case analyses

Full Text available with Trip Pro

2013 Cochrane

35. Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults. (PubMed)

Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults. Some antiepileptic drugs but not others are useful in clinical practice for the prophylaxis of migraine. This might be explained by the variety of actions of these drugs in the central nervous system. The present review is part of an update of a Cochrane review first published in 2004, and previously updated (conclusions not changed) in 2007.To describe and assess (...) the evidence from controlled trials on the efficacy and tolerability of antiepileptic drugs other than gabapentin, pregabalin, topiramate, and valproate (which are the subjects of separate Cochrane reviews) for preventing migraine attacks in adult patients with episodic migraine.We searched the Cochrane Central Register of Controlled Trials (CENTRAL; The Cochrane Library 2012, Issue 12), PubMed/MEDLINE (1966 to 15 January 2013), MEDLINE In-Process (current week, 15 January 2013), and EMBASE (1974 to 15

Full Text available with Trip Pro

2013 Cochrane

36. Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults. (PubMed)

Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults. Some antiepileptic drugs but not others are useful in clinical practice for the prophylaxis of migraine. This might be explained by the variety of actions of these drugs in the central nervous system. The present review is part of an update of a Cochrane review first published in 2004, and previously updated (conclusions not changed) in 2007.To describe and assess the evidence from controlled trials on the efficacy (...) and tolerability of gabapentin/gabapentin enacarbil or pregabalin for preventing migraine attacks in adult patients with episodic migraine.We searched the Cochrane Central Register of Controlled Trials (CENTRAL; The Cochrane Library 2012, Issue 12), PubMed/MEDLINE (1966 to 15 January 2013), MEDLINE In-Process (current week, 15 January 2013), and EMBASE (1974 to 15 January 2013) and handsearched Headache and Cephalalgia through January 2013.Studies were required to be prospective, controlled trials

Full Text available with Trip Pro

2013 Cochrane

37. A single preoperative dose of gabapentin does not improve postcesarean delivery pain management: a randomized, double-blind, placebo-controlled dose-finding trial (PubMed)

A single preoperative dose of gabapentin does not improve postcesarean delivery pain management: a randomized, double-blind, placebo-controlled dose-finding trial A single preoperative dose of 600 mg gabapentin, combined with multimodal analgesia, has previously been shown to reduce postcesarean pain and improve maternal satisfaction but was associated with increased maternal sedation. We hypothesized that a lower dose of gabapentin may be effective with less sedation.We conducted a doubleblind (...) , randomized, placebo-controlled study. Women undergoing elective cesarean delivery were randomized into 3 groups to receive 300 or 600 mg oral gabapentin, or placebo, 1 hour before surgery. Temporal summation (TS) testing was performed at the time of study drug administration, and a visual analog scale (0 to 100 mm) difference ≥10 mm between the 1st and 10th stimuli was considered TS+. Spinal anesthesia and postoperative analgesia were instituted, including intrathecal fentanyl and morphine, oral

Full Text available with Trip Pro

2012 EvidenceUpdates Controlled trial quality: predicted high

38. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. (PubMed)

Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Refractory chronic cough causes substantial symptoms and quality-of-life impairment. Similarities between central reflex sensitisation in refractory chronic cough and neuropathic pain suggest that neuromodulators such as gabapentin might be effective for refractory chronic cough. We established the efficacy of gabapentin in patients with refractory chronic cough.This randomised, double-blind, placebo (...) -controlled trial was undertaken at an outpatient clinic in Australia. Adults with refractory chronic cough (>8 weeks' duration) without active respiratory disease or infection were randomly assigned to receive gabapentin (maximum tolerable daily dose of 1800 mg) or matching placebo for 10 weeks. Block randomisation was done with randomisation generator software, stratified by sex. Patients and investigators were masked to assigned treatment. The primary endpoint was change in cough-specific quality

2012 Lancet Controlled trial quality: predicted high

39. Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain

Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage (...) evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain Arthur Jeske DMD, PhD; James Zahrowski DMD, MS, PharmD . Overview Systematic Review Conclusion Gabapentin (250 mg) is statistically superior to placebo for treating established acute postoperative pain. However, to achieve at least 50 percent pain relief over six hours, the number of patients needed to treat was 11, which suggests gabapentin has limited clinical value and is inferior to common analgesics

2011 ADA Center for Evidence-Based Dentistry

40. Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain

Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain Limited evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage (...) evidence does not support use of gabapentin as stand-alone therapy for acute postoperative pain Arthur Jeske DMD, PhD; James Zahrowski DMD, MS, PharmD . Overview Systematic Review Conclusion Gabapentin (250 mg) is statistically superior to placebo for treating established acute postoperative pain. However, to achieve at least 50 percent pain relief over six hours, the number of patients needed to treat was 11, which suggests gabapentin has limited clinical value and is inferior to common analgesics

2011 ADA Center for Evidence-Based Dentistry